Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Change in Receivables (2016 - 2025)

Regenxbio (RGNX) has 12 years of Change in Receivables data on record, last reported at $561000.0 in Q4 2025.

  • For Q4 2025, Change in Receivables rose 106.9% year-over-year to $561000.0; the TTM value through Dec 2025 reached $7.7 million, up 178.92%, while the annual FY2025 figure was $7.7 million, 178.92% up from the prior year.
  • Change in Receivables reached $561000.0 in Q4 2025 per RGNX's latest filing, down from $6.3 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $10.7 million in Q2 2022 and bottomed at -$22.0 million in Q4 2021.
  • Average Change in Receivables over 5 years is -$1.2 million, with a median of -$505500.0 recorded in 2025.
  • Peak YoY movement for Change in Receivables: crashed 251.61% in 2022, then surged 788.73% in 2025.
  • A 5-year view of Change in Receivables shows it stood at -$22.0 million in 2021, then soared by 77.99% to -$4.8 million in 2022, then soared by 30.45% to -$3.4 million in 2023, then tumbled by 141.41% to -$8.1 million in 2024, then soared by 106.9% to $561000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $561000.0 in Q4 2025, $6.3 million in Q3 2025, and $2.4 million in Q2 2025.